Diagnosis and treatment progress of metastatic cervical carcinoma with an unknown primary

doi:10.19401/j.cnki.1007-3639.2019.06.010

Abstract

Abstract: Metastatic cervical carcinoma with an unknown primary (MCCUP) represents a heterogeneous group syndrome of cancers. The current data were analyzed, and the diagnosis and treatment progress of MCCUP were stated. Positron emission tomography computed/tomography(PET/CT) has a high value in the detection of primary tumors in patients with MCCUP. Panendoscopy and molecular testing, such as microRNA signatures and microsatellite analysis, also improve the diagnosis of MCCUP. Surgery and radiation therapy remain the main approaches of MCCUP treatment. Most doctors agree that surgery is the first choice for patients with N_1-2disease. However, radiotherapy still plays an important role in the treatment of MCCUP. Today, salivarypreserving intensity-modulated radiation therapy has become the standard radiation technique for MCCUP.

Key words: Metastatic cervical carcinoma with an unknown primary, Diagnosis, Treatment, Progress

CHEN Jiaying, WANG Zhuoying. Diagnosis and treatment progress of metastatic cervical carcinoma with an unknown primary[J]. China Oncology, 2019, 29(6): 457-462.

[1]	ZHU Xinzhe, LI Hao, XU Huaxiang, LUO Guopei, YU Xianjun. Advances in basic research, clinical diagnosis and treatment of pancreatic cancer in 2021 [J]. China Oncology, 2022, 32(1): 1-12.
[2]	ZHANG Yan, CHEN Tongzhen, ZHU Xiaoli, LI Xiaoqiu. Analysis of clinicopathological features of human papilloma virus-associated oropharyngeal squamous cell carcinoma [J]. China Oncology, 2022, 32(1): 47-53.
[3]	ZHANG Chi, CHEN Jiahui, LIN Jinyi, WANG Yan, ZHANG Sijia, ZHU Wei, CHENG Leilei. Validation of a scale for evaluating the cardiovascular risk after breast cancer therapy: the clinical scale for breast cancer treatment related cardiovascular toxicity [J]. China Oncology, 2022, 32(1): 54-60.
[4]	JIN Yizi, LIN Mingxi, ZHANG Jian. Targeting DNA damage response deficiency in the treatment of breast cancer [J]. China Oncology, 2022, 32(1): 61-67.
[5]	Expert group of expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition) . Expert consensus on neoadjuvant treatment of breast cancer in China (2021 edition) [J]. China Oncology, 2022, 32(1): 80-89.
[6]	XU Ran , WANG Xinyue , FENG Linyuan , HAN Anna , WANG Yixuan , YANG Wanshan , LIU Chao . Expression and biological significance of NCAPD2 in glioma [J]. China Oncology, 2021, 31(9): 789-798.
[7]	LU Li, LU Renquan, SUN Jiajun, LU Ning, GUO Lin. The application of serum N-MID in auxiliary diagnosis and therapeutic effect monitoring of bone metastasis in patients with primary lung cancer [J]. China Oncology, 2021, 31(9): 838-844.
[8]	Tumor Support and Rehabilitation Therapy Group, the Oncology Committee of Chinese Medical Association. Clinical practice guidelines for cancer-related fatigue in China (2021 edition) [J]. China Oncology, 2021, 31(9): 852-872.
[9]	CONG Binbin, WANG Yongsheng. Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer [J]. China Oncology, 2021, 31(8): 689-696.
[10]	GAO Heli, XU Jin, YU Xianjun. Advances in clinical diagnosis and treatment of gastroenteropancreatic neuroendocrine tumor G3 [J]. China Oncology, 2021, 31(7): 567-573.
[11]	FENG Runlin , HUA Jie , KUI Xiang , LI Ruyi , YI Xiaojia , WANG Yan , TAO Yanping . A case report of metastatic pericardial myxoid liposarcoma and literature review [J]. China Oncology, 2021, 31(3): 227-230.
[12]	ZHOU Hongyu , LI Haoran , CHENG Xi , CHEN Lihua , YANG Yufei , CHANG Bin . Clinical characteristics of 11 patients with small cell carcinoma of the ovary, hypercalcemic type and literature review [J]. China Oncology, 2021, 31(2): 136-142.
[13]	YOU Chao , ZHENG Huizhong , JIANG Tingting , JIAN Jiahao , FAN Ming , LI Lihua , WU Jiong , GU Yajia , PENG Weijun . Differential diagnosis of mass lesions in digital breast tomosynthesis based on radiomics [J]. China Oncology, 2021, 31(12): 1162-1167.
[14]	LI Zeng , WU Yi , CHEN Zhuzhong , CHEN Li , LIAO Hong , MAO Dun , XIAO Yingming , XIE Hongping , LI Xiuli , YANG Shengke , ZHOU Shukui , ZHONG Lei , LU Hao , CHEN Yongji . The value of ¹⁸ F-PSMA-1007 PET/CT in the early diagnosis and clinical treatment of patients with biochemical recurrence after radical prostatectomy [J]. China Oncology, 2021, 31(11): 1081-1087.
[15]	SHEN Yujia , FU Xiaolong . Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer [J]. China Oncology, 2021, 31(11): 1115-1125.

Diagnosis and treatment progress of metastatic cervical carcinoma with an unknown primary

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments